Trials 18 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01496443 | Jan → May 2012 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT00949091 | Jan → Jul 2009 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01982253 | Oct 2013 → Jan 2014 | type 2 diabetes mellitus | Takeda | Terminated | No outcome recorded |
| Phase 2 | NCT01414920 | Aug 2011 → Aug 2012 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 2 | NCT01007097 | Dec 2009 → Sep 2010 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 313 trials | ||||||
| Phase 3 | NCT02015780 | Dec 2013 → Jan 2016 | chronic kidney disease, type 2 diabetes mellitus | Takeda | Withdrawn | No outcome recorded |
| Phase 3 | NCT01834274 | Jun 2013 → Mar 2014 | type 2 diabetes mellitus | Takeda | Terminated | No outcome recorded |
| Phase 3 | NCT01829464 | May 2013 → Feb 2014 | type 2 diabetes mellitus | Takeda | Terminated | No outcome recorded |
| Phase 3 | NCT01829477 | Apr 2013 → Feb 2014 | type 2 diabetes mellitus | Takeda | Terminated | No outcome recorded |
| Phase 3 | NCT01647542 | Oct 2012 → Feb 2014 | type 2 diabetes mellitus | Takeda | Terminated | No outcome recorded |
| Phase 3 | NCT01609582 | Jun 2012 → May 2014 | cardiovascular disorder, type 2 diabetes mellitus | Takeda | Terminated | No outcome recorded |
| Phase 3 | NCT01585792 | May → Dec 2012 | — | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01549964 | Apr 2012 → Mar 2014 | glucose metabolism disease | Takeda | Terminated | No outcome recorded |
| Phase 3 | NCT01481116 | Jan 2012 → Mar 2014 | type 2 diabetes mellitus | Takeda | Terminated | No outcome recorded |
| Phase 3 | NCT01433419 | Jan → Dec 2012 | diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01456195 | Nov 2011 → Jul 2013 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01433406 | Oct 2011 → Dec 2013 | diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01433393 | ? → Sep 2012 | diabetes mellitus | Takeda | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fasiglifam | “Due to potential concerns about liver safety, on balance, the benefits of treating patients with fasiglifam (TAK-875) do not outweigh the potential risks.” NCT01647542 ↗8“Due to potential concerns about liver safety, on balance, the benefits of treating patients with fasiglifam (TAK-875) do not outweigh the potential risks.” NCT01481116 ↗ “Due to potential concerns about liver safety, on balance, the benefits of treating patients with fasiglifam (TAK-875) do not outweigh the potential risks.” NCT01829477 ↗ “The drug being tested in this study is called TAK-875 (fasiglifam).” NCT01829464 ↗ |
| Known as | AK875 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1829174 ↗ |
| Known as | CPD 9A | ChEMBL registry synonym — accepted as the source's own label CHEMBL1829174 ↗ |
| Known as | TAK-875 | “The purpose of this study is to determine the efficacy and safety of TAK-875 (fasiglifam), once daily (QD), in participants with type 2 diabetes mellitus (T2DM).” NCT01456195 ↗15“TAK-875 is under clinical development for the treatment of type 2 diabetes mellitus in humans.” NCT01007097 ↗ “Fasiglifam (TAK-875) tablets” NCT01834274 ↗ “Fasiglifam (TAK-875) tablets” NCT01549964 ↗ |
| Known as | TAK-875 ANHYDROUS | ChEMBL registry synonym — accepted as the source's own label CHEMBL1829174 ↗ |
| Action | Activate | “selective pharmacological activation of this receptor by TAK-875” PMID 22374408 ↗ Feb 20121“Free fatty acid receptor 1 positive allosteric modulator” CHEMBL1829174 ↗ |
| Modality | Small molecule | — CHEMBL1829174 ↗ |
| Route | Oral | “TAK-875 25 mg tablets, orally” NCT00949091 ↗ |
| Target | FFAR1 | “Free fatty acid receptor 1 positive allosteric modulator” CHEMBL1829174 ↗ |